FDA Blessed "Alleviates Bloating." Here Is the List.

which bloating phrases did fda call acceptable structure/function claims?

FDA called a tight set of gas and bloating phrases acceptable structure/function claims, which means claims about normal body function rather than disease treatment. In the Jan. 6, 2000 final-rule preamble, FDA adopted the old antiflatulent monograph language: "Alleviates the symptoms referred to as gas," "alleviates bloating," "alleviates pressure," "alleviates fullness," and "alleviates stuffed feeling." That is the rare case where an advertiser does not have to infer the allowed wording from enforcement silence.

This list is the reason digestion and bloating sit apart from parasite cleanse, liver detox and disease-named gut offers. We checked the source language against the fact pack because this page turns on exact wording, not a general comfort level. If your claim stays close to "alleviates bloating" and avoids disease context, FDA gave you more to work with than it gave most supplement categories.

That does not make the phrase magic.

• Use "alleviates bloating" for the symptom, not "treats IBS bloating" for a disease-linked symptom.
• Use "alleviates pressure" or "alleviates fullness" where the creative stays in ordinary digestive discomfort.
• Keep the 21 CFR 101.93 disclaimer with lawful structure/function statements; the disclaimer is a condition, not a cure.

why did fda accept them and reject stronger digestive wording?

FDA accepted those phrases because gas, bloating, pressure, fullness and stuffed feeling are nonspecific symptoms with many causes, not characteristic signs of one disease. The operating rule is 21 CFR 101.93(g)(2), which says FDA looks at whether the statement explicitly or implicitly claims an effect on disease, including characteristic signs or symptoms "using scientific or lay terminology." That last phrase matters because ordinary consumer wording can still become a disease claim.

The line is clearest in heartburn. FDA said "relief of sour stomach" and "upset stomach" can be structure/function claims, and it allowed occasional heartburn and occasional acid indigestion because sporadic overindulgence can produce those symptoms. But the same preamble says recurrent or persistent heartburn and acid indigestion can be hallmarks of significant illness, so those become disease claims. One adjective changes the legal footing.

"Occasional" is doing the work.

Constipation works the same way but with a warning label attached. FDA allowed "For relief of occasional constipation" after reversing its proposed position, but said the labeling should make clear the product is not for chronic constipation. If your copy says chronic constipation, IBS-C or bowel obstruction, the safe harbor is gone. The stress-copy equivalent is why FDA-listed calm claims are useful only while they stay away from diagnosable anxiety or depression.

what else in the same preamble is quotable for digestion copy?

The same FDA preamble gives digestion advertisers three more usable anchors: "helps promote digestion," "helps maintain regularity," and motion-related nausea language from the antiemetics monograph. FDA said a claim that a product "helps promote digestion" is a structure/function claim because it does not refer expressly or implicitly to a disease state. That sentence is dull copy, but it is operationally valuable copy.

For regularity, the safer construction is maintenance, not rescue. "Helps maintain regularity" says the product supports normal function; "fixes constipation" pushes toward treatment. This is the same pattern as occasional sleeplessness, where the permitted word narrows the claim to an ordinary, non-disease condition instead of insomnia.

We would rather buy boring defensible words than exciting words that put the whole funnel in a warning letter.

The motion-sickness language is a special case and should not be casually imported into general digestive copy. FDA allowed "for the prevention and treatment of the nausea, vomiting, or dizziness associated with motion" as structure/function wording in that preamble, but that does not authorize nausea claims tied to pregnancy, chemotherapy, infection or another disease context. The phrase survives because the context is motion, not because nausea is always safe.

• Useful: "helps promote digestion."
• Useful: "helps maintain regularity."
• Useful only in its own context: motion-associated nausea, vomiting or dizziness.
• Not useful: claims linked to IBS, GERD, Crohn's, ulcerative colitis, diverticulitis, celiac disease or SIBO.

how far does the safe harbor extend before it breaks?

The safe harbor extends only as far as the whole page still reads like ordinary digestive support rather than disease treatment. FDA's own rule says, "FDA will consider the context in which the claim is presented," so the sentence, product name, ingredient rationale, testimonials, Amazon listing and linked blog can all matter. We counted that as the main compliance trap because advertisers often clean the headline and leave the disease claim elsewhere.

JLM Nutritionals is the cleanest warning. In the 2021 IBSolution letter, FDA wrote, "Your product name implies use for the treatment of Irritable Bowel Syndrome (IBS)." FDA also cited the FAQ, Amazon copy, consumer testimonials and the ibsformula.com domain. The claim did not fail because bloating is forbidden; it failed because the offer was built around IBS relief.

Most operators in this niche would argue that a compliant bloating page can keep a symptom comparison visual if the copy avoids IBS and chronic-disease framing; the evidence supports them more than platform folklore does. 21 CFR 101.93(g)(2)(iv)(E) covers pictures only when the picture implies an effect on disease, and FDA's examples are disease signals such as ECG tracings, diseased organs and the Rx symbol. A belly visual is not automatically a disease claim, but it becomes one when the page surrounds it with IBS, GERD or chronic constipation cues.

• Breaks by disease name: IBS, GERD, Crohn's, ulcerative colitis, diverticulitis, celiac disease, SIBO.
• Breaks by persistence: recurrent heartburn, persistent acid indigestion, chronic constipation.
• Breaks by product naming: IBSolution, IBS formula, GERD relief or similar names.
• Breaks by evidence placement: a blog post or study citation linked to purchase can become intended-use evidence.

does a picture of a flat stomach carry a claim the copy avoided?

A flat-stomach image can carry a claim the copy avoided, but the FDA question is whether the image implies disease treatment in context. A distended-to-flat sequence next to "alleviates bloating" is different from the same image next to IBS, chronic constipation or "recurrent acid reflux." The image becomes part of the claim environment, not a separate decoration.

Meta adds a different filter. Its Health and Wellness policy, per the verified fact pack, prohibits clickbait tactics in health, weight-loss or weight-gain ads, including sensational language, extreme claims and specific-outcome promises within a set timeframe without disclaimers. That means a "debloat in 3 days" visual can fail platform review even if the FDA wording stays closer to a structure/function claim.

The landing page is in scope.

For media buying, the practical move is to audit the visual, the time promise and the body-area treatment together. A plain product-and-benefit ad is one thing. A pinched abdomen, a countdown and a dramatic before/after sequence is another. We could not verify a current Meta-published numeric strike count for health-account violations; a live platform page stating the strike threshold would settle it.

if the wording is lawful, does the advertiser still need proof?

Yes, lawful FDA wording still needs FTC substantiation before it runs. FDA classification asks whether the statement is a structure/function claim or a disease claim; FTC asks whether the advertiser had adequate proof before making the claim. Those are parallel tests. A bloating claim can pass the first test and still fail the second.

The FTC's 2022 Health Products Compliance Guidance says, "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing." That is the bar many digestion offers miss because they rely on ingredient plausibility, supplier decks, in vitro studies or a small open-label trial. FTC also says evidence must be sufficient in quality and quantity when considered against the full body of reliable evidence.

Dannon is the reference case for why this matters. In the Activia and DanActive matter, the FTC challenged claims around temporary irregularity, slow intestinal transit time, colds and flu; the final order was issued Feb. 4, 2011, and Dannon separately paid $21 million to 39 state attorneys general. The lesson for your offer is narrow: good phrasing does not substitute for good evidence. The FTC source record is available through the Dannon case materials.

The same FTC logic applies to testimonials. If a reviewer says the product fixed acid reflux, IBS or chronic constipation, the advertiser has not avoided the claim by letting a customer say it. Moderation is part of compliance because FDA and FTC both treat consumer-facing claims as evidence of the seller's message. That is also why blood sugar claim wording has to be audited across ads, labels, pages and reviews, not just the primary headline.

what does the bloating buyer actually look like on media plans?

The bloating buyer is broader, younger and more female-skewing than the general supplement buyer. The strongest audience anchor in the fact pack is the Rome Foundation Global Epidemiology Study, which analyzed 51,425 people in 26 countries and found that nearly 18% reported bloating at least once per week in the prior 3 months. Prevalence decreased with age, and women were approximately twice as likely as men to report bloating.

That changes the media plan. General supplement data skews older, but bloating demand does not need an older-health frame to make sense. A 27-year-old buyer who wants to wear fitted clothing after lunch is a different creative problem from a 63-year-old liver-support buyer. The Rome study also found high overlap with other gastrointestinal symptoms, including 71.4% weekly bloating among people reporting weekly epigastric pain, per the Gastroenterology abstract.

A Danish blood-donor survey gives a second directional check, not a US rate card. In 53,046 healthy, self-selected adults surveyed from Nov. 2020 to Mar. 2023, 68% reported at least 1 of 13 gastrointestinal symptoms, and bloating tied abdominal rumbling at 40%. Because the cohort is non-US and self-selected, we would use it as a symptom-commonness signal, not as a precise US targeting percentage.

The buyer is usually symptomatic, not diagnosed.

how should a digestion offer be audited against this list?

A digestion offer should be audited by starting with FDA's blessed words, then reading the entire funnel for context that changes their meaning. We would mark "alleviates bloating," "helps promote digestion" and "helps maintain regularity" as usable starting points, then review the name, H1, advertorial, ingredient page, references, testimonials, marketplace listings, email copy and retargeting ads.

The second pass is the disease pass. Delete IBS, IBS-C, GERD, Crohn's, ulcerative colitis, diverticulitis, celiac disease and SIBO unless the business is prepared to be treated as marketing a drug. Tighten heartburn to occasional heartburn, constipation to occasional constipation, and add the chronic-constipation carve-out FDA described. If your product name or domain carries the disease, copy edits will not solve the core problem.

The third pass is proof. For each remaining claim, map the exact sentence to the evidence file. FTC's health-products guidance is the source to use here because the substantiation rule is independent of FDA taxonomy; the FTC guidance is explicit that randomized, controlled human clinical testing is generally needed for health-related benefits. A supplier's mechanism story is not the same thing.

Finally, audit the platform layer separately. Google, Meta and TikTok can reject or restrict ads for reasons that are narrower, broader or simply different from FDA classification. Meta's review covers ad text, images, targeting and landing pages, while Google treats health as a sensitive interest category and limits audience tools for those campaigns. Your legal wording can still be a bad media-buying asset if it depends on personalized medical copy or dramatic body imagery.

• Keep: ordinary bloating, gas, fullness, pressure and regularity language.
• Qualify: heartburn, acid indigestion and constipation.
• Remove: disease names, chronicity, prescription comparisons and therapy-substitute framing.
• Check: testimonials, Amazon pages, social posts and linked educational content.
• Document: substantiation before launch, not after a rejected ad or regulator letter.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Which Supplement Categories Draw the Most FTC Attention, How to Choose a Nutra Niche: A Constraint-First Decision Framework, Candida and Yeast Offers: A Market Built on an Unofficial Diagnosis, Overweight vs Obesity: The Line FDA Drew for Ads, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.